Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema

PURPOSE: To evaluate the safety and preliminary efficacy of THR-687 in patients with center-involved diabetic macular edema (DME). DESIGN: Phase 1, open-label, multicenter, 3 + 3 dose-escalation study with 3-month follow-up. PARTICIPANTS: Patients 18 years of age or older with visual impairment resu...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanani, Arshad M., Patel, Sunil S., Gonzalez, Victor H., Moon, Suk J., Jaffe, Glenn J., Wells, John A., Kozma, Petra, Dugel, Pravin U., Maturi, Raj K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562295/
https://www.ncbi.nlm.nih.gov/pubmed/36247818
http://dx.doi.org/10.1016/j.xops.2021.100040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562295/
https://www.ncbi.nlm.nih.gov/pubmed/36247818
http://dx.doi.org/10.1016/j.xops.2021.100040

Ejemplares similares